TGF-β INHIBITORS ARE NOVEL DRUGS -IN DIABETIC NEPHROPATHY a REVIEW

Soni, Navneet Omprakash

doi:10.20959/wjpps20178-9815

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A new potential target in diabetic nephropathy has been identified. [43][44][45][46][47][48][49][50][51][52][53][54][55][56][57] The Wnt/β-catenin signaling pathway is involved in mesangial cell extracellular matrix (ECM) production (MCs). 58 Through the JNK/NF-B/NADPH oxidase/ROS pathway, high glucose promotes renal mesangial cell proliferation and fibronectin expression.…”

Section: Diabetic Nephropathymentioning

confidence: 99%

Berbamine application beyond cancer

Soni¹

2021

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

The main purpose of this review was to ascertain the clinical application and future non oncological uses of Berbaminebamine (BERBAMINE). Berbaminebamine, as a STAT3 (signal transducer and activator of transcription) inhibitor, antioxidant, anti-inflammatory and modulator of many signalling pathways, should be investigated in autoimmune diseases. Berbaminebamine has been found to have pharmacological activity in the following cancers: breast cancer, lung cancer, prostate cancer, pancreatic cancer, ovarian cancer, glioblastoma, colon cancer, bladder cancer, chronic myeloid leukemia, hepatocellular carcinoma, triple negative breast cancer and osteosarcoma. Ischemic reperfusion injury, melanoma, COVID-19 and allergy diseases are among the conditions for which it is beneficial. It may aid in the treatment of obesity, metabolic syndrome, inflammatory syndrome, sepsis, COVID-19, dengue fever, Nipah virus infection, influenza, solid tumors, lymphoma, cancer, hematological malignancies, skin inflammatory disorder and atopic dermatitis. BERBAMINE can be used as versatile molecule in alcoholic liver disease, diabetic nephropathy and antiviral, anti-inflammatory.

show abstract

Section: Diabetic Nephropathymentioning

confidence: 99%

Berbamine application beyond cancer

Soni¹

2021

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…A number of innovative treatments have also been verified in the investigational diabetic model and humans together with exercise, inhibitors of the renin-angiotensin system (RAAS) (angiotensin type 1 receptor blockers, angiotensin-converting enzyme inhibitors), inhibitors of advanced glycation end products (AGEs) like pyridoxamine, peroxisome proliferator-activated receptor PPAR new drug targets like histone deacetylase inhibitors which are still in embryonic stage, fibroblast activation protein inhibitors, nicotinamide adenine dinucleotide phosphate oxidase inhibitors and transforming growth factor beta 1 signalling as novel target for treatment of DN and various other molecular drug target are highlighted. [1][2][3][4][5] PPREs, the isoforms of receptor PPAR α,β/δ,γ are recognized many agonist and antagonist are been highlighted in many review article. 6 Recently PPAR-δ activation by GW610742 renovates albuminuria by thwarting diabetes-induced nephrin loss and restoring podocyte integrity, implying that GW610742 may be a potential therapeutic agent for diabetic nephropathy.…”

Section: Introductionmentioning

confidence: 99%

Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy

Soni¹,

Pawar²,

Kale³

et al. 2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Diabetic nephropathy is global problem with several drugs into trial without much success the current article highlights the role of thiazolidinedione’s in diabetic nephropathy by scrutinizing and reconnoitring the cellular and intracellular mechanism and shielding action and the role of peroxisome proliferator-activated gamma receptors (PPARγ) receptors. Not only anti-diabetic action but renal protective effect with evidence based study has been highlighted. PPAR γ-is versatile target having numerous benefits and mainly preventing fibrosis in diabetic experimental model and some clinical case report yet, the benefits are not up to mark, since renal failure itself causes volume expansion and the thiazolidinedione’s (TZDs) also preserve salt and water and lead to congestive heart failure which constraints its clinical application. Dual activators and balaglitazone selective PPAR modulator are having upcoming potential for treatment of diabetic nephropathy. Further detail investigation on such drug is needed to explore. However adverse effect like heart failure, osteoporosis and volume expansion effect over-rides the beneficial effect thus limiting its clinical use of currently available TZDs.

show abstract

TGF-β INHIBITORS ARE NOVEL DRUGS -IN DIABETIC NEPHROPATHY a REVIEW

Cited by 2 publications

References 0 publications

Berbamine application beyond cancer

Berbamine application beyond cancer

Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy

Contact Info

Product

Resources

About